Research & DevelopmentGlycadia's experienced R&D team is bringing new scientific discoveries to clinical trials of innovative products for complications of diabetes, including nephropathy, retinopathy and cardiovascular disease.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Product | Indication | Preclinical | Clinical | ||
| Phase I | Phase II | Phase III | |||
| GLY-230 | Diabetic Nephropathy |  |
|
|
|
| GLY-230 | Diabetic Retinopathy | |
|
||
| GLY-220 | Macrovascular Disease | |
|||
| A717 | Diabetic Nephropathy | |
|||
| A717 | Diabetic Retinopathy | |
|||
| CAP22 | Macrovascular Disease | |
|||
| GLY-230 | Alzheimer's Disease | |
|||
Glycadia Pharmaceuticals 1880 JFK Blvd, Suite 200 Philadelphia, PA 19103
Tel 215.557.8021 · Fax 215.557.8053
Tel 215.557.8021 · Fax 215.557.8053
Developing safe and effective treatments for diabetic complications.™